In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
New data from Pfizer and BioNTech’s Comirnaty program show the firms’ updated jab produces antibodies against the latest variants of the coronavirus. 14 October 2022
Pharmaceutical
The Russian pharmaceutical sector is steadily developing despite the ongoing military conflict in Ukraine and the ever-tightening sanctions pressure against the country, according to recent statements by some leading local pharma analysts and Russian media, reports The Pharma Letter’s local correspondent. 14 October 2022
Biotechnology
Russia has been faced with a shortage of Oncaspar (pegaspargase), a drug from French independent pharma major Servier, which is designed for the treatment of leukemia in children. 14 October 2022
Biotechnology
A significant late stage trial win lifted GSK stock by around 1.5% in early morning trading on Friday, with the company hailing the result as “truly exceptional.” 14 October 2022
Biotechnology
Late-stage US biotech Relmada Therapeutics’ shares sank 78% to $7.00 by mid-morning, after it revealed that its RELIANCE III study (REL-1017-303), evaluating REL-1017 in the monotherapy setting for major depressive disorder (MDD), did not achieve its primary endpoint. 13 October 2022
Biotechnology
Australian drug discovery company AdAlta and venture-backed Korean biotech GPCR Therapeutics have announced a collaboration. 13 October 2022
Pharmaceutical
The migraine market has seen the introduction of a large number of highly effective monoclonal antibody (Mab) drugs for the prevention of the condition, leading to expectations for the overall therapy sector to grow from $4.7 billion in 2020 to $12 billion in 2030 across the seven major markets. 13 October 2022
Biotechnology
US biotech Novavax has reported potentially important results on its COVID-19 vaccine NVX-CoV2373. 13 October 2022
Biotechnology
Sino-American biotech BeiGene shot up on Wednesday, after the company's chronic lymphocytic leukemia (CLL) treatment was shown to beat out a blockbuster drug from Johnson & Johnson. 13 October 2022
Biotechnology
Shares of US biotech Moderna leapt almost 12% to $134.96 yesterday, after it announced that pharma giant Merck & Co has opted to develop a personalized cancer vaccine based on messenger RNA technology. 13 October 2022
Biotechnology
Updated results from the Phase I/II STAAR trial are good enough for Sangamo Therapeutics to trigger the expansion phase of the study. 13 October 2022
Biotechnology
The US Food and Drug Administration yesterday said it has amended the emergency use authorizations (EUAs) for two COVID-19 vaccine, bivalent to authorize their use as a single booster dose in younger age groups. 13 October 2022
Biosimilars
An Expert View from Mark Samuels, chief executive, British Biosimilars Association. 12 October 2022
Pharmaceutical
French therapeutic peptides for rare endocrine and metabolic diseases company Amolyt Pharma today announced positive Phase IIa safety and efficacy data from the second cohort of its ongoing clinical trial evaluating its lead candidate, AZP-3601, in patients with hypoparathyroidism. 12 October 2022
Biotechnology
GSK subsidiary Sierra Oncology has returned rights for oncology candidate SRA737 to the CRT Pioneer Fund (CPF), a joint initiative between commercialization and development company Cancer Research Technology and the European Investment Fund. 12 October 2022
Biotechnology
Denmark-based clinical-stage firm Evaxion Biotech, which specializes in the development of AI-driven immunotherapies, announced that its new chief executive Per Norlén joined the company on October 3. 12 October 2022
Biotechnology
US precision oncology start-up Tavros Therapeutics and Vividion Therapeutics, a biopharma company that was snapped by German pharma major Bayer last year, have entered into a collaboration to discover or target four oncology targets across an initial five-year term. 12 October 2022
Biotechnology
Boston-based Albireo Pharma, a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, closed more than 14% higher after Tuesday’s trading. 12 October 2022
Pharmaceutical
Japanese pharma major Astellas today released positive 52-week results from the Phase III SKYLIGHT 4 clinical study evaluating the safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. 12 October 2022
Biosimilars
Inflation across Europe has now risen above 10%. As a result, this has increased the manufacturing costs of essential, off patent medicines, which account for 70% of those dispensed in Europe. 12 October 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze